PROMACTA Drug Patent Profile

Which patents cover Promacta, and when can generic versions of Promacta launch?

Promacta is a drug marketed by Novartis and is included in two NDAs. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the eltrombopag olamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Promacta

A generic version of PROMACTA was approved as eltrombopag olamine by ANNORA PHARMA on April 18^th, 2024.

Summary for PROMACTA

International Patents:	135
US Patents:	6
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PROMACTA

Paragraph IV (Patent) Challenges for PROMACTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PROMACTA	Tablets	eltrombopag olamine	12.5 mg and 25 mg	022291	1	2014-02-04
PROMACTA	Tablets	eltrombopag olamine	50 mg and 75 mg	022291	1	2014-01-07

US Patents and Regulatory Information for PROMACTA

PROMACTA is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-004	Oct 20, 2011	AB	RX	Yes	No					Y
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-002	Nov 20, 2008	AB	RX	Yes	No					Y
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-003	Sep 8, 2009	AB	RX	Yes	Yes					Y
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-001	Nov 20, 2008	AB	RX	Yes	No					Y
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-004	Oct 20, 2011	AB	RX	Yes	No					Y
Novartis	PROMACTA	eltrombopag olamine	TABLET;ORAL	022291-001	Nov 20, 2008	AB	RX	Yes	No					Y

International Patents for PROMACTA

When does loss-of-exclusivity occur for PROMACTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Poland

Portugal

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering PROMACTA around the world.

Country	Patent Number	Title	Estimated Expiration
Eurasian Patent Organization	020883
Hong Kong	1113057
Denmark	1534390
Cyprus	1109730
Hungary	E027209
Denmark	3090730

Supplementary Protection Certificates for PROMACTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1534390	91 3-2010	Slovakia		PRODUCT NAME: ELTROMBOPAG; REGISTRATION NO/DATE: EU/1/10/612/001 - EU/1/10/612/006 20100315
1294378	2010C/018	Belgium		PRODUCT NAME: ELTROMBOPAG, OPTIONNELLEMENT SOUS FORME DE SEL OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (Y COMPRIS UN HYDRATE); AUTHORISATION NUMBER AND DATE: EU/1/10/612/001 20100315
1294378	SPC/GB10/026	United Kingdom		PRODUCT NAME: ELTROMBOPAG, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE (INCLUDING A HYDRATE); REGISTERED: UK EU1/10/612/001 20100315; UK EU1/10/612/002 20100315; UK EU1/10/612/003 20100315; UK EU1/10/612/004 20100315; UK EU1/10/612/005 20100315; UK EU1/10/612/006 20100315
1294378	SPC020/2010	Ireland		SPC020/2010: 20110308, EXPIRES: 20250310
1534390	C20100006	Estonia		PRODUCT NAME: REVOLADE-ELTROMBOPAG; AUTHORISATIN NO.: EMA/CHMP/697489/2018; AUTHORISATION DATE: 20181019
1534390	C 2010 013	Romania		PRODUCT NAME: ELTROMBOPAG; NATIONAL AUTHORISATION NUMBER: RO EU/1/10/612/001, RO EU/1/10/612/002, RO EU/1/10/612/003, RO EU/1/10/612/004, RO EU/1/10/612/005, RO EU/1/10/612/006; DATE OF NATIONAL AUTHORISATION: 20100311; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/10/612/001, EMEA EU/1/10/612/002, EMEA EU/1/10/612/003, EMEA EU/1/10/612/004, EMEA EU/1/10/612/005, EMEA EU/1/10/612/006; DATE OF FIRST AUTHORISATION IN EEA: 20100311

PROMACTA (Eltrombopag) Investment Analysis: Patent Expiry and Market Dynamics

Last updated: February 19, 2026

PROMACTA (eltrombopag) faces imminent patent expiry, creating a critical juncture for investment decisions. The drug, developed by GlaxoSmithKline (GSK), is a thrombopoietin receptor agonist used to treat thrombocytopenia. Its market exclusivity period is set to conclude, opening the door for generic competition and necessitating a thorough evaluation of its remaining market potential and the competitive landscape.

What is PROMACTA's Current Market Position?

PROMACTA is approved for several indications, primarily in the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to corticosteroids or other treatments. It also holds approvals for thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection to enable or maintain platelet counts, and for severe aplastic anemia (SAA) in patients who have had an insufficient response to immunosuppressive therapy.

In 2022, PROMACTA generated $1.84 billion in revenue for GSK. This revenue is distributed across its various indications, with chronic ITP representing a significant portion of its sales. The drug's efficacy in improving platelet counts and reducing bleeding events has established its clinical utility and patient adherence.

When is PROMACTA's Key Patent Protection Expiring?

The primary patent protecting PROMACTA, U.S. Patent No. 7,598,257, covering eltrombopag's core chemical entity, is set to expire on December 10, 2024. This date marks the end of its U.S. market exclusivity. While GSK may hold other secondary patents related to manufacturing processes, formulations, or specific uses, the expiration of the core composition of matter patent is the most significant driver of generic entry.

European patent protection for eltrombopag also expires in a similar timeframe. For instance, European patent EP 1 517 925 B1, which also covers the compound, has a term that is effectively ending. The exact expiry dates can vary by country due to patent term extensions and supplementary protection certificates (SPCs).

What is the Market Size and Growth Potential for Thrombocytopenia Treatments?

The global market for thrombocytopenia treatments is substantial and projected to grow. The prevalence of ITP, aplastic anemia, and HCV infection, all contributing to thrombocytopenia, drives demand.

• Immune Thrombocytopenia (ITP): The incidence of ITP varies, with estimates suggesting around 5-10 new cases per 100,000 people annually in Western countries. The chronic form affects a significant portion of these patients, creating a sustained market for treatment.
• Aplastic Anemia: This rare but serious condition affects approximately 2-6 individuals per million per year. SAA, a more severe form, requires aggressive treatment, including agents like eltrombopag.
• Hepatitis C Virus (HCV): Although significant progress has been made in HCV treatment with direct-acting antivirals (DAAs), a substantial number of patients still require management of thrombocytopenia during treatment, especially in regions where DAAs are not universally accessible or for patients with specific co-morbidities.

The global thrombocytopenia market was valued at approximately $7.5 billion in 2022 and is expected to reach $10.1 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.3% from 2022 to 2029 (Source: Fortune Business Insights). This growth is fueled by increasing disease prevalence, rising healthcare expenditure, and advancements in diagnostic and therapeutic options.

Who are the Key Competitors and Potential Generic Entrants?

With the expiration of PROMACTA's primary patents, generic manufacturers are poised to enter the market. Companies that have historically demonstrated capabilities in producing complex small molecules and have active dockets for generic oncology and hematology drugs are likely candidates.

• Generic Manufacturers: While specific companies may not have publicly declared their intent for eltrombopag generics due to ongoing litigation or strategic reasons, companies such as:

  • Viatris
  • Teva Pharmaceuticals
  • Lupin
  • Sun Pharmaceutical Industries
  • Dr. Reddy's Laboratories

  These companies are known to pursue opportunities upon patent expiry of significant pharmaceuticals. Their ability to secure regulatory approvals and establish manufacturing capacity will be critical.

• Competitive Landscape (Current): PROMACTA competes with other treatments for ITP, including:

  • Corticosteroids: Prednisone, dexamethasone are first-line treatments.
  • Immunoglobulins (IVIg): Used for rapid platelet count increases.
  • Other Thrombopoietin Receptor Agonists (TPO-RAs):
    • Nplate (romiplostim) by Amgen: Also a TPO-RA, Nplate is a marketed competitor to PROMACTA, albeit with a different administration route (subcutaneous injection).
    • Avatrombopag (Mulpleo) by Bristol Myers Squibb: Another oral TPO-RA that gained approval, presenting direct competition.
  • Splenectomy: A surgical option for some ITP patients.

The introduction of generic eltrombopag will significantly alter this landscape by introducing a lower-cost alternative.

What is the Expected Impact of Generic Competition on PROMACTA's Pricing and Market Share?

Generic entry typically leads to a rapid and substantial decline in the brand-name drug's market share and average selling price (ASP).

• Price Erosion: For branded drugs, the introduction of generics can lead to price reductions of 80-90% or more within the first year of generic availability. PROMACTA's ASP is expected to follow this trend.
• Market Share Shift: Generic versions will capture a significant portion of the market demand, particularly for price-sensitive payers and patients. GSK's market share for eltrombopag will diminish accordingly. The extent of this decline depends on factors such as the number of generic entrants, their pricing strategies, and payer formularies.
• Volume vs. Value: While the value of PROMACTA sales will decrease significantly, the overall volume of eltrombopag units prescribed might remain high or even increase due to the lower price, making it more accessible.

Historical data from other blockbuster drugs entering generic markets demonstrates this pattern. For example, the launch of generic atorvastatin (Lipitor) led to a dramatic drop in the branded drug's revenue, while the overall market for statins expanded.

What are the Remaining Opportunities and Risks for Investors?

Investors considering PROMACTA's post-patent expiry scenario face both opportunities and risks.

Opportunities:

• Generic Manufacturer Investment: Investing in established generic pharmaceutical companies with strong manufacturing capabilities and established distribution networks can be a viable strategy. These companies are positioned to benefit from the demand for eltrombopag generics.
• Market Growth of Thrombocytopenia Treatments: The underlying market for thrombocytopenia treatments is expected to continue growing, driven by disease prevalence. Even with price erosion for eltrombopag, the overall therapeutic area remains robust.
• Continued Clinical Utility: PROMACTA and its generic equivalents will remain clinically effective treatment options. Physicians may continue to prescribe eltrombopag based on its established efficacy and safety profile.

Risks:

• Rapid Price Erosion: The speed and depth of price decline post-patent expiry are significant risks for the brand-name manufacturer. Investors in GSK would see a sharp revenue drop from PROMACTA.
• Intense Generic Competition: A large number of generic entrants can lead to aggressive price competition, further impacting profitability for all players, including generic manufacturers.
• Regulatory Hurdles: While patents are the primary barrier, any unforeseen regulatory challenges for generic versions or ongoing litigation related to secondary patents could delay market entry or impact accessibility.
• Emergence of Novel Therapies: The development of new, potentially superior therapies for ITP or other thrombocytopenia indications could displace eltrombopag, even its generic forms.
• Payer Policies: Favorable formulary placement for competing therapies or strict prior authorization requirements for eltrombopag could limit its market penetration.

What is the Outlook for PROMACTA's Brand and Generic Equivalents Post-2024?

Following the expiry of the core patent in December 2024, PROMACTA, as a branded product, will transition into a period of significant market share and revenue decline. GSK will likely focus on managing the decline, potentially through inventory management and continued marketing to physicians who may prefer the established brand for a period.

The generic versions of eltrombopag will become the dominant force in the market. Their success will be contingent on several factors:

• Timely FDA Approval: Generic manufacturers will aim for swift approval from the U.S. Food and Drug Administration (FDA) to capitalize on the market opening.
• Cost-Effective Manufacturing: The ability to produce eltrombopag at a low cost will be crucial for competitive pricing.
• Supply Chain Reliability: Ensuring consistent supply to meet market demand is paramount.
• Physician and Payer Adoption: Generic uptake will depend on how quickly physicians and payers embrace the new, lower-cost alternatives.

The long-term outlook for eltrombopag, as a molecule, remains positive due to its established clinical profile in treating specific patient populations with thrombocytopenia. However, the economic value attributed to the branded product will be substantially diminished. For investors, the focus will shift from the branded pharmaceutical company to the generic manufacturers that can effectively capture market share through competitive pricing and efficient operations.

Key Takeaways

• PROMACTA's core U.S. patent expires in December 2024, initiating a period of significant market change.
• The global thrombocytopenia treatment market is substantial and projected to grow, indicating continued demand for eltrombopag.
• Generic entry is expected to cause a rapid decline in PROMACTA's pricing and market share.
• Opportunities exist for investors in generic pharmaceutical companies poised to capitalize on the eltrombopag generic market.
• Risks include aggressive price competition among generics and the potential emergence of novel therapeutic agents.

Frequently Asked Questions

Will PROMACTA be discontinued by GSK after patent expiry?

GSK is unlikely to immediately discontinue PROMACTA. They will likely manage the product through the transition to generic competition, focusing on its established patient base and potentially leveraging remaining secondary patents or marketing efforts. However, sales revenue will significantly decrease.

How many generic manufacturers are likely to enter the market?

The number of generic entrants is difficult to predict precisely but is expected to be substantial, given the drug's revenue potential. Companies with established generic portfolios in hematology and oncology are probable candidates.

What is the typical timeframe for generic price erosion after launch?

Generic price erosion typically begins immediately upon launch and can reach 80-90% within the first year, with further declines occurring over subsequent years as competition intensifies.

Will eltrombopag be more affordable after patent expiry?

Yes, eltrombopag will become significantly more affordable once generic versions are available, making it accessible to a broader patient population and potentially increasing overall utilization.

Are there any clinical advantages of PROMACTA over its generic equivalents?

No. Once generic versions are approved by regulatory bodies such as the FDA, they are considered therapeutically equivalent to the branded product, meaning they contain the same active ingredient and are absorbed by the body at the same rate and extent.

Citations

[1] Fortune Business Insights. (2023). Thrombocytopenia Market Size, Share & COVID-19 Impact Analysis, By Treatment Type (Therapy, Drug Class), By Indication (ITP, Cancer, Liver Disease, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecasts, 2023-2029. Retrieved from https://www.fortunebusinessinsights.com/thrombocytopenia-market-77780